Search
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. … Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating
Phosphatidyl serine
go.drugbank.com/drugs/DB00144ApprovedNutraceuticalIn apoptosis, phosphatidyl serine is transferred to the outer leaflet of the plasma membrane. This is part of the process by which the cell is targeted for phagocytosis. … PS has been shown to slow cognitive decline in animal models.
Guanfacine
go.drugbank.com/drugs/DB01018ApprovedInvestigationalGuanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release … tablet for the treatment of ADHD.
Categories: Antihypertensive Agents Indicated for HypertensionRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience. … [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541]
Pentoxyverine
go.drugbank.com/drugs/DB11186ApprovedWithdrawn[L43942] Other forms of pentoxyverine citrate continue to be marketed. … Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties.
Tegaserod
go.drugbank.com/drugs/DB01079ApprovedWithdrawnin female patients less than 65 years of age and whom are considered to be at a lower risk of a cardiovascular event than the broader population. … [L5918,F4229] Since then, closer evaluations of the original data suggesting such cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically
Categories: Drugs for Constipation, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDexbrompheniramine
go.drugbank.com/drugs/DB00405ApprovedDexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Categories: Antihistamines for Systemic UsePinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalIt is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable … Pinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function.
Categories: Drugs for Functional Gastrointestinal DisordersBelzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L36105] Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and inhibit these proteins. … This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired